Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Alzheimer’s Association Business Consortia (AABC)

The mission of the AABC is to advance Alzheimer’s disease (AD) research and innovation in small, start-up biotechnology, diagnostic and contract research organizations.

The AABC works to achieve their mission by working on areas of common interest in a pre-competitive space to advance both the field of Alzheimer’s research and the member company’s goals. The AABC member companies provide leadership and direction to the organization’s areas of focus that include but are not limited to:


Collaborations are very valuable to small companies as a way to share resources, expand infrastructure, save money and potentially create income. The consortia will provide a platform for companies looking for collaboration opportunities within the consortia between member companies. The Alzheimer’s Association will provide a space on their web-site for the consortia companies to share information and develop relationships. The consortia members will also share ideas on how to develop collaborations with large companies external to the consortia.

AABC Meetings

The next meeting will be scheduled for early 2018.

Recognition & Visibility

Small companies will benefit from publications and positive publicity. As such, the AABC will look for ways to bring companies in this sector to the attention of the AD R&D community through publications and posters. As an example, the AABC may present a poster at an upcoming AAIC.

Knowledge and Information Sharing

The AABC will look for ways to share knowledge and information in a pre-competitive space. The group will share information about each member companies. They may also share information on trusted consultants, CRO’s, ways to manage data in a small company, funding strategies and funding sources.


May 2017


Company summaries


Agenda/Meeting Minutes

February 1, 2017

December 9, 2016

October 19, 2015

August 25, 2015

July 21, 2015

May 13, 2015

March 2, 2015

November 18, 2014





Speaker: Declan Jones, Vice President, Neuroscience Lead, J&J Innovation Center
Wednesday, February 24, 2016 11:00 A.M. ET / 8:00 A.M. PT

Translational Animal Models

For the purposes of the AABC Working Group, the following description of Alzheimer's disease translational models is proposed.

Translational animal models of Alzheimer's disease should parallel both the development of progressive clinical pathology in humans with Alzheimer's disease as well as the symptomatology including deficits across multiple cognitive domains and in activities of daily living. Interventions that change the course of pathology or cognitive/symptomatic outcomes in the animal models will be validated if they also change the course of pathology in Alzheimer's patients in a similar fashion, or vice versa. To enhance their utility for drug discovery purposes, the pathological features measured over the course of the disease may include fluid-based biomarkers and metabolites, changes in brain/body pathologies measured by MRI or PET, biochemical changes in the brain detected by MRS, post-mortem neuropathological hallmarks of the disease as well as synaptic loss and inflammation, and quantifiable changes in cognitive function measured using multi-cognitive domain specific testing.

The validity of animal models to predict likely effects in human clinical trials is challenging for neurological diseases such as Alzheimer's disease due to species differences across numerous factors. As such, the limitations of each animal model must be recognized. In general, the animal model with the fewest number of limitations will have the greatest potential value to predict human outcomes. A further challenge is to decide which clinical outcomes are the most informative for predicting clinical success of Alzheimer's disease therapeutics. Since Alzheimer's disease develops over time, the clinical outcomes measured may need to be different at different disease stages, or times of disease progression, and animal models demonstrating a greater number of testable modalities that parallel this progressive nature of the disease will have greater value.

For more information

For investigators who are interested in more information on the AABC, please contact James A. Hendrix, Ph.D.

James A. Hendrix, Ph.D.
Director, Global Science Initiatives, Medical and Scientific Relations
Alzheimer's Association


Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.